<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777671</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-126</org_study_id>
    <nct_id>NCT02777671</nct_id>
  </id_info>
  <brief_title>Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers</brief_title>
  <official_title>Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, randomised, open-label, two-way crossover study to investigate whether&#xD;
      multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) affects the&#xD;
      pharmacokinetics of gliclazide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>before the gliclazide dose, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h post-gliclazide dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Gliclazide following a single oral dose of 80 mg administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>before the gliclazide dose, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h post-gliclazide dose</time_frame>
    <description>Time to maximum observed concentration (Tmax) of Gliclazide following a single oral dose of 80 mg administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12</measure>
    <time_frame>before the gliclazide dose, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h post-gliclazide dose</time_frame>
    <description>Area under the plasma concentration-time curve over 12 hours (AUC0-12) of Gliclazide following a single oral dose of 80 mg administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>before the gliclazide dose, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h post-gliclazide dose</time_frame>
    <description>Area under the concentration-time curve from time zero up to infinity with extrapolation of the terminal phase (AUC0-∞) of Gliclazide following a single oral dose of 80 mg administered alone</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>tablets containing gliclazide 80 mg (Diamicron® 80 mg)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects were eligible for the study if they fulfilled all of the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          -  Male or female subjects aged between 18 and 45 years, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) between 19 and 30 kg/m2, inclusive.&#xD;
&#xD;
          -  Healthy as determined by pre-study medical history, physical examination, vital signs,&#xD;
             complete neurological examination and 12-lead ECG.&#xD;
&#xD;
          -  Negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening&#xD;
&#xD;
          -  Clinical laboratory test results clinically acceptable at screening and admission to&#xD;
             each treatment period.&#xD;
&#xD;
          -  Negative screen for alcohol and drugs of abuse at screening and admission to each&#xD;
             treatment period.&#xD;
&#xD;
          -  Non-smokers or who smoke ≤ 10 cigarettes or equivalent per day.&#xD;
&#xD;
          -  Able and willing to give written informed consent.&#xD;
&#xD;
          -  (If female) Not of childbearing potential by reason of surgery or, if of childbearing&#xD;
             potential, she used one of the following methods of contraception: double barrier or&#xD;
             intrauterine device.&#xD;
&#xD;
          -  (If female) Negative urine pregnancy test at screening and admission to each treatment&#xD;
             period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects were not eligible for the study if they fulfilled any of the following exclusion&#xD;
        criteria:&#xD;
&#xD;
          -  Clinically relevant history or presence of respiratory, gastrointestinal, renal,&#xD;
             hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective&#xD;
             tissue diseases or disorders.&#xD;
&#xD;
          -  Clinically relevant surgical history.&#xD;
&#xD;
          -  History of relevant atopy or drug hypersensitivity.&#xD;
&#xD;
          -  History of alcoholism or drug abuse.&#xD;
&#xD;
          -  Consumed more than 14 units of alcohol a week.&#xD;
&#xD;
          -  Significant infection or known inflammatory process at screening or admission to each&#xD;
             treatment period.&#xD;
&#xD;
          -  Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the&#xD;
             time of screening or admission to each treatment period.&#xD;
&#xD;
          -  Used medicines within 2 weeks of admission to first period that may affect the safety&#xD;
             or other study assessments, in the investigator's opinion.&#xD;
&#xD;
          -  Used any investigational drug or participated in any clinical trial within 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Participated in more than 2 clinical trials within the 12 months prior to screening.&#xD;
&#xD;
          -  Donated or received any blood or blood products within the 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Vegetarians, vegans or with medical dietary restrictions.&#xD;
&#xD;
          -  Could not communicate reliably with the investigator.&#xD;
&#xD;
          -  Unlikely to co-operate with the requirements of the study.&#xD;
&#xD;
          -  Unwilling or unable to give written informed consent.&#xD;
&#xD;
          -  (If female) Pregnant or breast-feeding.&#xD;
&#xD;
          -  (If female) Of childbearing potential and she did not use an approved effective&#xD;
             contraceptive method (double-barrier or intra-uterine device) or she used oral&#xD;
             contraceptives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Human Pharmacology Unit</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4745-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

